Together with BioNTech, the pharmaceutical company will test 144 volunteers to find out if a booster injection could increase protection against the British, South African and Brazilian versions of the coronavirus
A Pfizer it’s at BioNTech started a study this Thursday, 25, to find out that if a third dose of their vaccine against Covid-19 could guarantee protection against new variants do coronavirus. Pharmaceutical companies have already concluded that the recommended standard of two doses of the immunizer has a lower immune response to the new strains of Sars-Cov-2. Now, the idea is to give a third injection of the vaccine to 144 volunteers who have already received the first two doses between 6 and 12 months ago. In the sequence, these people will be exposed to the new variants of the coronavirus on three occasions: shortly after receiving the third dose, after a week and after a month.
Pfizer and BioNTech have not specified when they will have the results of this research, which will show whether one more application of the immunizer is capable of increasing the effectiveness against the British, South African and Brazilian versions of the virus. Pharmaceutical companies also plan to develop a new vaccine against Covid-19 that acts specifically against variants, considered more transmissible than the version that gave rise to the pandemic.